| 3 0.285 (10.5%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.72 | 1-year : | 4.09 |
| Resists | First : | 3.18 | Second : | 3.5 |
| Pivot price | 2.97 |
|||
| Supports | First : | 2.66 | Second : | 2.21 |
| MAs | MA(5) : | 2.99  |
MA(20) : | 2.93 |
| MA(100) : | 4.3 |
MA(250) : | 4.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.6 |
D(3) : | 34.7 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 9.5 | Low : | 2.59 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ DWTX ] has closed below upper band by 44.8%. Bollinger Bands are 63.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.09 - 3.11 | 3.11 - 3.13 |
| Low: | 2.68 - 2.7 | 2.7 - 2.72 |
| Close: | 2.97 - 3 | 3 - 3.03 |
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Mon, 23 Mar 2026
HC Wainwright Issues Positive Forecast for DWTX Earnings - MarketBeat
Sun, 22 Mar 2026
If You Invested $1,000 in Dogwood Therapeutics (DWTX) - Stock Titan
Fri, 20 Mar 2026
What is HC Wainwright's Estimate for DWTX FY2030 Earnings? - MarketBeat
Wed, 18 Mar 2026
Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates - AlphaStreet
Wed, 18 Mar 2026
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - markets.businessinsider.com
Wed, 18 Mar 2026
DWTX: Halneuron® Phase 2b trial advances, with funding secured through key 2026 milestones - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 75.2 (%) |
| Held by Institutions | 11 (%) |
| Shares Short | 66 (K) |
| Shares Short P.Month | 91 (K) |
| EPS | -25.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -14.43 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.1 % |
| Return on Equity (ttm) | -931 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | -0.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|